Ocular Therapeutix Inc (OCUL)
6.17
+0.30
(+5.11%)
USD |
NASDAQ |
May 03, 16:00
5.66
-0.51
(-8.27%)
After-Hours: 07:32
Ocular Therapeutix Enterprise Value: 796.15M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 796.15M |
| May 02, 2024 | 751.56M |
| May 01, 2024 | 625.23M |
| April 30, 2024 | 583.61M |
| April 29, 2024 | 592.53M |
| April 26, 2024 | 584.36M |
| April 25, 2024 | 503.35M |
| April 24, 2024 | 569.49M |
| April 23, 2024 | 622.26M |
| April 22, 2024 | 633.40M |
| April 19, 2024 | 654.95M |
| April 18, 2024 | 750.07M |
| April 17, 2024 | 1.006B |
| April 16, 2024 | 1.037B |
| April 15, 2024 | 1.038B |
| April 12, 2024 | 1.067B |
| April 11, 2024 | 1.110B |
| April 10, 2024 | 1.055B |
| April 09, 2024 | 1.093B |
| April 08, 2024 | 1.067B |
| April 05, 2024 | 1.134B |
| April 04, 2024 | 1.138B |
| April 03, 2024 | 1.135B |
| April 02, 2024 | 1.139B |
| April 01, 2024 | 1.171B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.232B |
| March 27, 2024 | 1.263B |
| March 26, 2024 | 1.246B |
| March 25, 2024 | 1.278B |
| March 22, 2024 | 1.290B |
| March 21, 2024 | 1.388B |
| March 20, 2024 | 1.351B |
| March 19, 2024 | 1.321B |
| March 18, 2024 | 1.282B |
| March 15, 2024 | 1.285B |
| March 14, 2024 | 1.255B |
| March 13, 2024 | 1.304B |
| March 12, 2024 | 1.260B |
| March 11, 2024 | 1.325B |
| March 08, 2024 | 1.362B |
| March 07, 2024 | 1.420B |
| March 06, 2024 | 1.489B |
| March 05, 2024 | 1.136B |
| March 04, 2024 | 1.130B |
| March 01, 2024 | 1.115B |
| February 29, 2024 | 1.036B |
| February 28, 2024 | 1.023B |
| February 27, 2024 | 1.017B |
| February 26, 2024 | 1.017B |
| February 23, 2024 | 1.013B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.98M
Minimum
May 23 2019
1.663B
Maximum
Dec 22 2020
471.43M
Average
344.99M
Median
Dec 06 2021
Enterprise Value Benchmarks
| Amgen Inc | 221.30B |
| Assertio Holdings Inc | 62.61M |
| CytomX Therapeutics Inc | 125.50M |
| EyePoint Pharmaceuticals Inc | 652.61M |
| Regeneron Pharmaceuticals Inc | 96.91B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.22M |
| Revenue (Quarterly) | 14.80M |
| Total Expenses (Quarterly) | 34.85M |
| EPS Diluted (Quarterly) | -0.35 |
| Gross Profit Margin (Quarterly) | 90.64% |
| Profit Margin (Quarterly) | -197.4% |
| Earnings Yield | -20.26% |
| Normalized Earnings Yield | -21.94 |